Secondary endpoint data from the EMBARK trial support use of enzalutamide treatments in patients with high-risk biochemically recurrent prostate cancer.
Because treatment of the whole prostate can lead to long-term side effects in patients with prostate cancer, interest in ...
LUPRON DEPOT (leuprolide acetate for extended-release injectable suspension) is a hormonal medication first approved by Health Canada in 1989 for advanced prostate cancer, and later for various ...
A PSA of 127 indicated a high probability of prostate cancer, leading to immediate Lupron ADT therapy and radiation treatment. Initial diagnosis and treatment left the author feeling weak and ...
The FINANCIAL — Abbott Park, Illinois — Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved a new 45 mg for six-month administration formulation of Lupron Depot® ...
Following the 2025 ESMO Congress, Dr. Joshua Saba sat down with Dr. Chandler Park to discuss recent advances in prostate cancer care. Following the 2025 European Society of Medical Oncology (ESMO) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results